ANNX — Annexin Pharmaceuticals AB (publ) Share Price
0.000.00%
Last trade - 00:00- SEK93.58m
- SEK72.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.97 | ||
| Price to Tang. Book | 5.07 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -234.8% | ||
| Return on Equity | -179.93% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | 40 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 5th, 2014
- Public Since
- April 19th, 2017
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 346,583,688
- Address
- Drottninggatan 65, STOCKHOLM, 111 36
- Web
- https://www.annexinpharma.com/
- Phone
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for ANNX
Similar to ANNX
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Annexin Pharmaceuticals AB (publ) share price?
As of Today at 19:02 UTC, shares in Annexin Pharmaceuticals AB (publ) are trading at SEK0.27. This share price information is delayed by 15 minutes.
How has the Annexin Pharmaceuticals AB (publ) share price performed this year?
Shares in Annexin Pharmaceuticals AB (publ) last closed at SEK0.27 and the price had moved by -59.67% over the past 365 days. In terms of relative price strength the Annexin Pharmaceuticals AB (publ) share price has underperformed the FTSE Global All Cap Index by -62.14% over the past year.
What are the analyst and broker recommendations for Annexin Pharmaceuticals AB (publ)?
There is no consensus recommendation for this security.
What is the Annexin Pharmaceuticals AB (publ) dividend yield?
Annexin Pharmaceuticals AB (publ) does not currently pay a dividend.
Does Annexin Pharmaceuticals AB (publ) pay a dividend?
Annexin Pharmaceuticals AB (publ) does not currently pay a dividend.
When does Annexin Pharmaceuticals AB (publ) next pay dividends?
Annexin Pharmaceuticals AB (publ) does not currently pay a dividend.
How do I buy Annexin Pharmaceuticals AB (publ) shares?
To buy shares in Annexin Pharmaceuticals AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Annexin Pharmaceuticals AB (publ)?
As of the previous close price of SEK0.27, shares in Annexin Pharmaceuticals AB (publ) had a market capitalisation of SEK93.58m.
Where are Annexin Pharmaceuticals AB (publ) shares listed?
Here are the trading details for Annexin Pharmaceuticals AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ANNX
What kind of share is Annexin Pharmaceuticals AB (publ)?
Based on an overall assessment of its quality, value and momentum Annexin Pharmaceuticals AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Annexin Pharmaceuticals AB (publ) share price forecast for 2024?
The analyst consensus target price for shares in Annexin Pharmaceuticals AB (publ) is SEK1.20. That is 344.44% above the last closing price of SEK0.27.
Analysts covering Annexin Pharmaceuticals AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Annexin Pharmaceuticals AB (publ) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Annexin Pharmaceuticals AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -39.05%.
As of the last closing price of SEK0.27, shares in Annexin Pharmaceuticals AB (publ) were trading -25.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Annexin Pharmaceuticals AB (publ) PE Ratio?
The Annexin Pharmaceuticals AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Annexin Pharmaceuticals AB (publ)?
We do not have data on Annexin Pharmaceuticals AB (publ)'s directors